Gut
Audio Summaries

Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism

Jun 23, 2026

The authors investigate how Schwann cells (SCs) are activated in the fibrotic microenvironment of pancreatic ductal adenocarcinoma (PDAC), given the known roles of fibrosis and tumor innervation in cancer lethality. They find that increased stiffness in the stroma correlates with heightened SC activation through a nuclear mechanosensing mechanism, specifically involving c-Jun phosphorylation and the enzyme phospholipase A2. This study suggests that pancreatic fibrosis alone can activate SCs, potentially influencing therapeutic strategies targeting the tumor microenvironment in PDAC.

Functional anti-preS1 antibody responses associated with viral control in chronic hepatitis B

Jun 22, 2026

The authors investigate the serological and functional significance of preS1 antigen and anti-preS1 IgG in chronic hepatitis B (CHB) to understand their roles in viral control. They find that while preS1 antigen levels correlate with HBV replication, high levels of anti-preS1 IgG are associated with effective viral neutralization and sustained virological suppression after therapy withdrawal, indicating its potential as a marker for host immune control in CHB.

Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies

Jun 17, 2026

The authors aim to explore the genetic underpinnings of both pediatric and adult cholestatic liver diseases, particularly focusing on the implications of identified variants in PFIC-associated genes for treatment options. They discuss the potential for personalized therapies, such as intestinal bile acid transporter inhibitors, in managing pruritus and other symptoms in patients with varying onset ages of cholestasis. The review seeks to provide insights into how genetic analysis can inform treatment strategies for cholestatic liver diseases.

Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia

Jun 17, 2026

This study aims to identify predictors and outcomes of chronic hepatitis delta (CHD) in a large cohort of 565 patients with at least three years of follow-up from the D-SOLVE and HDV-1000 consortia. The findings indicate that older age, elevated gamma-glutamyl transferase levels, cirrhosis, and detectable HDV RNA are significant determinants of liver-related events, with a notably worse prognosis associated with HDV RNA levels ≥1000 IU/mL.

Combined acetaldehyde metabolism burden modifies IBD susceptibility to alcohol consumption

Jun 17, 2026

The authors aimed to investigate how variations in alcohol metabolism, specifically the burden of acetaldehyde metabolism, influence the relationship between alcohol consumption and the risk of inflammatory bowel disease (IBD). Their findings indicate that individuals with low acetaldehyde burden experience a protective effect from red wine consumption, while those with high burden face increased IBD risk, highlighting the need to consider individual metabolic differences in IBD prevention strategies.

SPP1⁺ macrophages facilitate the differentiation and maturation of regulatory T cells in tumour-draining lymph nodes of colorectal cancer

Jun 12, 2026

This study investigates the role of SPP1⁺ macrophages in the differentiation and maturation of regulatory T cells (Tregs) within tumour-draining lymph nodes (TDLNs) in colorectal cancer (CRC). The authors aim to identify immunomodulatory mechanisms that contribute to Treg maturation and immunosuppression in CRC, revealing that SPP1⁺ macrophages promote the development of immunosuppressive CD137⁺ Tregs through the SPP1-CD44-NF-κB1 signaling pathway. Targeting this pathway may provide a therapeutic strategy to mitigate Treg-mediated immunosuppression in CRC.

Microbiota and metabolites modulation of cancer stem cells and chemotherapy sensitivity

Jun 11, 2026

This review explores how the microbiota and its metabolites influence cancer stem cells (CSCs) and their role in chemotherapy resistance. The authors aim to elucidate the mechanisms by which commensal microbes and their metabolites affect CSC function and the tumor microenvironment, while also discussing potential therapeutic strategies to target these interactions to enhance chemosensitivity and improve patient outcomes.

Dual mechanism of immune escape shapes the genetic and immunogenic landscape of mismatch repair-deficient colorectal tumours

Jun 11, 2026

The authors aim to understand how host immunity influences the genomic architecture and tumor microenvironment of mismatch repair-deficient (MMRd) colorectal cancers. Their findings reveal a dual mechanism of immune escape—immunoediting and local immunosuppression—that allows MMRd tumors to persist despite being immunogenic, highlighting potential therapeutic vulnerabilities for neoantigen-based or immune reactivation strategies.

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial

Jun 10, 2026

The authors aimed to compare the 10-year risks of colorectal cancer (CRC) mortality, incidence, and all-cause mortality between one-time colonoscopy and sustained biennial fecal immunochemical testing (FIT) in the COLONPREV Trial. Their analysis revealed similar risks for CRC incidence and all-cause mortality between the two screening strategies, while colonoscopy showed a lower but imprecise estimate for CRC mortality. The findings underscore the significance of adherence in interpreting outcomes from pragmatic screening trials.

Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective

Jun 5, 2026

The authors aimed to assess the global prevalence of chronic kidney disease (CKD) in patients with cirrhosis and its impact on their prognosis. They found that CKD was present in 18.17% of hospitalized cirrhosis patients, particularly in high-income countries, and was associated with significantly lower kidney function, more complications, and higher mortality rates. The study highlights the need for improved management strategies for CKD in cirrhosis patients to enhance their outcomes.